Introduction of nucleic acid amplification testing of plasma pools - Implications for an integrated blood service

Infusionstherapie und Transfusionsmedizin

Volumn 25, Issue 2-3, 1998, Pages 94-97

  Snape, T ^a   Flanagan, P ^b  

^a BIO PRODUCTS LABORATORY   (United Kingdom)

^b NHS BLOOD AND TRANSPLANT   (United Kingdom)

Author keywords

Fractionation; HCV RNA; Minipool testing; Plasma pools; Virus safety

Indexed keywords

ARTICLE; BLOOD BANK; DISEASE TRANSMISSION; FRACTIONATION; GENE AMPLIFICATION; NUCLEIC ACID ANALYSIS; SAFETY;

HEPATITIS C VIRUS; RNA VIRUSES;

EID: 0031839018     PISSN: 10198466     EISSN: None     Source Type: Journal    
DOI: 10.1159/000053401     Document Type: Article

References (11)

1. CDC: Outbreak of Hepatitis C associated with intravenous immunoglobulin administration - United States, October 1993-June 1994. MMWR 1994;43: 505-509.
2. Yu MW, Mason BL, Guo ZP, Tankersley DL, Nedjar S, Mitchell FD, Biswas RM: Hepatitis C transmission associated with intravenous immunoglobulins. Lancet 1995;345:1173-1174.
3. Scribner C: Dear Manufacturer letter. Center of Biologics Evaluation and Research, December 27, 1994.
4. Zoon KC: Dear Manufacturer letter. Center of Biologies Evaluation and Research, March 3, 1995.
5. Nübling CM, Willkommen H, Löwer J: Hepatitis C transmission associated with intravenous immunoglobulins. Lancet 1995;345:1174.
6. CPMP: Intramuscular Immunoglobulins: Nucleic acid amplification tests for HCV RNA detection. Recommendation CPMP/117/95.
7. Schreiber GB, Busch MP, Kleinman SH: The risk of transfusion transmitted viral infections. N Engl J Med 1996;334:1685-1690.
8. Mortimer J: Intersecting pools and their potential application in testing donated blood for viral genomes. Vox Sang 1997;73:93-96.
9. Smith DM, Lipton KS: Current status of PCR testing of pooled samples of recovered plasma. AABB Bulletin 1997:6.
10. Schottstedt V, Tuma W, Hunger G: Identification of a single viraemic donation with PCR-minipool testing in a large blood bank. Transfusion Med 1997;7 (suppl):14.
11. Paul-Ehrlich-Institut: Bekanntmachung über die Zulassung und Registrierung von Arzneimitteln (Abwehr von Arzneimittelrisiken, Stufe H-Verminderung des Risikos von Hepatitis-B-, Hepatitis-C- und HIV-Infektionen bei Empfängern von Erythrozytenkonzentraten) vom 18.3.1997: Anhörung zur Auflage einer Testung auf HIV-1-, HBV- und HCV-Genome mit Nukleinsäure-Amplifikationstechniken bei Erythrozytenkonzentraten. Bundesanzeiger 63, 4. April 1997.